Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors

Acta Oncol. 2009;48(8):1213-5. doi: 10.3109/02841860902980453.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / adverse effects*
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Female
  • Hoarseness / chemically induced*
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / blood supply
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism
  • Signal Transduction
  • Vascular Endothelial Growth Factors / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factors
  • Bevacizumab